BRTX Key Statistics, Chart & Performance
The current stock price of BRTX is 1.18 USD. In the past month the price increased by 9.26%. In the past year, price decreased by -27.61%.
BRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About BRTX
Company Profile
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 11 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The company also operates a commercial biocosmeceutical platform.
Company Info
BIORESTORATIVE THERAPIES INC
40 Marcus Drive
Melville NEW YORK US
CEO: Lance Alstodt
Employees: 11
Phone: 16317608100
BIORESTORATIVE THERAPIES INC / BRTX FAQ
Can you describe the business of BIORESTORATIVE THERAPIES INC?
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 11 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The company also operates a commercial biocosmeceutical platform.
What is the stock price of BIORESTORATIVE THERAPIES INC today?
The current stock price of BRTX is 1.18 USD. The price increased by 0.85% in the last trading session.
Does BRTX stock pay dividends?
BRTX does not pay a dividend.
What is the ChartMill rating of BIORESTORATIVE THERAPIES INC stock?
BRTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for BIORESTORATIVE THERAPIES INC?
BIORESTORATIVE THERAPIES INC (BRTX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for BIORESTORATIVE THERAPIES INC?
BIORESTORATIVE THERAPIES INC (BRTX) will report earnings on 2026-03-25, before the market open.
What is the Short Interest ratio of BIORESTORATIVE THERAPIES INC (BRTX) stock?
The outstanding short interest for BIORESTORATIVE THERAPIES INC (BRTX) is 1.79% of its float.
BRTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BRTX. When comparing the yearly performance of all stocks, BRTX is a bad performer in the overall market: 88.89% of all stocks are doing better.
BRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BRTX. While BRTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
BRTX Financial Highlights
Over the last trailing twelve months BRTX reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 4.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -224.55% | ||
| ROE | -574.11% | ||
| Debt/Equity | 0 |
BRTX Forecast & Estimates
8 analysts have analysed BRTX and the average price target is 13.26 USD. This implies a price increase of 1023.73% is expected in the next year compared to the current price of 1.18.
For the next year, analysts expect an EPS growth of -42.84% and a revenue growth 0.12% for BRTX